Acumen Pharma News Today

/PRNewswire/ -- cTRL Therapeutics, a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and...

(Bloomberg) -- European stocks rose on Tuesday as investor focus started to turn to company earnings from economic data and monetary policy. Novartis AG climbed after raising its profit outlook and announcing plans for a share buyback of up to $15 billion.Most Read from BloombergSingapore Passport Is World’s Most Powerful, Replacing JapanTesla Investor Rode a 14,800% Gain Thanks to 27-Year-Old AnalystMassive US Oil Caverns Sit Empty and Will Take Years to RefillTokyo Heat Smashes 150-Year...

Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheimer's disease.